Cocrystal Pharma Files To Start Human Trial For Protease Inhibitor In COVID-19

Cocrystal Pharma Files To Start Human Trial For Protease Inhibitor In COVID-19
  • Cocrystal Pharma Inc COCP has submitted a pre-Investigational New Drug (IND) briefing package to the FDA for its broad-spectrum protease inhibitor CDI-45205 in COVID-19.
  • FDA's response is expected to provide greater clarity and guidance on designing Phase 1 and Phase 2 trials for CDI-45205.
  • Related Link: Cocrystal Pharma's Preclinical Protease Inhibitor Effective Against Original, Two Variant COVID-19 Strains.
  • CDI-45205 is among protease inhibitors obtained under an exclusive license agreement with Kansas State University Research Foundation (KSURF) in 2020.
  • CDI-45205 and several analogs showed potent in vitro activity against the variants, surpassing the activity observed with the original Wuhan strain.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: COCP shares are up 5.92% at $0.95 on Monday.
Posted In: BriefsCOVID-19 CoronavirusPhase 1 TrialPhase 2 TrialBiotechLong IdeasNewsPenny StocksHealth CareFDAMoversTrading IdeasGeneral